Organizations

Vertex Pharmaceuticals (Canada) Inc.

Vertex Pharmaceuticals (Canada) Inc. has met with MPs 6 times since January 2024, reaching 6 MPs across 2 parties. Most recent contact: June 4, 2026.

6 meetings since 20248 all-time6 MPs2 parties0% by in-house staff

What they're asking for

In the registry's own words. Descriptions are only filed for meetings since mid-2024.

  1. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

    June 4, 2026 · Juanita Nathan · Liberal · Health; Industry; Intellectual Property; Science and Technology; Budget

  2. Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy

    March 24, 2026 · Dan Mazier · Conservative · Health; Industry; Intellectual Property; Science and Technology; Budget

  3. Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.

    November 19, 2025 · Michael Coteau · Liberal · Health; Industry; Budget

Full meeting log

6 MP-directed communications since January 2024, from the Registry of Lobbyists.

DateMP
2026-06-04Juanita Nathan · Liberal
2026-03-24Dan Mazier · Conservative
2026-03-10Tom Kmiec · Conservative
2026-03-10Salma Zahid · Liberal
2026-03-09Judy A. Sgro · Liberal
2025-11-19Michael Coteau · Liberal
Counts include only communications where a sitting MP is the named public office holder — meetings with ministers' staff, senators, or departments are not shown. Registrants self-report these records. See our methodology.